Cardiovascular System
Heart, Valve - Degeneration, Myxomatous
Narrative
Elangbam CS. 2010. Drug-induced valvulopathy: An update. Toxicol Pathol 38:837-848.
Abstract: https://www.ncbi.nlm.nih.gov/pubmed/20716786Elangbam CS, Colman KA, Lightfoot RM, Tyler RD, Wall HG. 2002. Endocardial myxomatous change in Harlan Sprague-Dawley rats (Hsd:S-D) and CD-1 mice: Its microscopic resemblance to drug-induced valvulopathy in humans. Toxicol Pathol 30:483-491.
Abstract: https://www.ncbi.nlm.nih.gov/pubmed/12187939Elangbam CS, Job LE, Zadrozny LM, Barton JC, Yoon LW, Gates LD, Slocum N. 2008. 5-Hydroxytryptamine (5HT)-induced valvulopathy: Compositional valvular alterations are associated with 5HT2B receptor and 5HT transporter transcript changes in Sprague-Dawley rats. Exp Toxicol Pathol 60:253-262.
Abstract: https://www.ncbi.nlm.nih.gov/pubmed/18511249Elangbham CS, Wehe JG, Barton JC, Krull DL, Nyska A, Crabbs T, Kissling G. 2007. Evaluation of glycosaminoglycans content and 5-hydroxytryptamine 2B receptor in rat heart valves with spontaneous mitral valvulopathy - a possible exacerbation by dl-amphetamine sulfate in Fischer 344 rats? Exp Toxicol Pathol 58:89-99.
Abstract: https://www.ncbi.nlm.nih.gov/pubmed/16996724